Figure 2
![Figure 2. Platelet responses during the treatment period in all placebo- and romiplostim-treated patients and in patients by age cohort. (A) Median (25th [Q1] and 75th [Q3] percentiles) number of weeks that platelet counts were 50 × 109/L or greater during the treatment period. Platelet counts within 4 weeks of administration of rescue medication were excluded from these analyses. (B) Percent of patients who had platelet counts of 50 × 109/L or greater for 2 consecutive weeks in the absence of rescue medication. (C) Percent of patients who had an increase in platelet counts of 20 × 109/L or greater above baseline for 2 consecutive weeks in the absence of rescue medication.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/1/10.1182_blood-2010-10-313908/4/zh89991172640002.jpeg?Expires=1735498466&Signature=VET6ZubXabEXxAnxvwWb3kh--5~s6CTF8whc0Zo3QgjTz1T3bjQAHunzXFzf5bKjqeBXiPLI1-~-QKhGhM45kWNhuDuSe2mVKk--hRa8nlhLx1YCRx4kNQ6iKIX6AYyxl~DoK-2Qq~ZoilMlE-JcoPV42b8xh47rfDmFsdGo00XiWZrh7j3g6xOnUhV5o1ojgDa9-PyP0a-xjAeR84VoTMFbmNWIE5mRkJUSSWfV1XByVJxcOrUF~Nr1WG1dKQsos2uJWYd5kmnt4gJaeY36o5TLs14DPVabq-ZOvJCzbhnUbmwq61qac2I5A-eAXYor4wQNkaL3e2KQ2ZZqYCXmoQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Platelet responses during the treatment period in all placebo- and romiplostim-treated patients and in patients by age cohort. (A) Median (25th [Q1] and 75th [Q3] percentiles) number of weeks that platelet counts were 50 × 109/L or greater during the treatment period. Platelet counts within 4 weeks of administration of rescue medication were excluded from these analyses. (B) Percent of patients who had platelet counts of 50 × 109/L or greater for 2 consecutive weeks in the absence of rescue medication. (C) Percent of patients who had an increase in platelet counts of 20 × 109/L or greater above baseline for 2 consecutive weeks in the absence of rescue medication.
